|Bid||82.04 x 2000|
|Ask||82.44 x 2500|
|Day's Range||81.64 - 82.08|
|52 Week Range||81.64 - 82.08|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
McDonald’s, Boeing, Novartis, Southwest Airlines and Foxconn are the companies to watch.
Yahoo Finance's Julie Hyman discusses Novartis International's goals and partnership with Tilray with company CEO, Vasant Narasimhan.
(Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of ...
Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines..
Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines.
Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland's 20 largest listed companies, market operator SIX said on Tuesday. Information about any other changes to SMI and Switzerland's other indexes will be released later, the bourse said. Novartis last year announced the spin off of Alcon to the Basel drugmaker's shareholders in the first half of this year.
The biotech world is feverishly awaiting the FDA's potential approval of a gene therapy called Zolgensma, a spinal muscular atrophy treatment, that is expected from Novartis in May.
Novartis AG (NVS) reported fourth-quarter results before the opening bell on Wednesday. Warning! GuruFocus has detected 2 Warning Sign with NVS. By segment, sales in the innovative medicines business increased 5.4% year over year to $9.022 billion, sales from the Sandoz division fell 5.2% from the prior-year quarter to $2.459 billion and Alcon sales rose 1.5% to $1.788 billion.
Novartis earnings and sales lagged expectations early Wednesday, as the drug giant guided to low- to mid-single digit sales growth in 2019. Novartis stock was down on the news.
Novartis Chief Executive Vas Narasimhan said he will be ready to discuss the future of generics unit Sandoz following a revamp due to take 18 months, while still calling the business "an integral part" of the Swiss drugmaker. "We consider Sandoz an integral part of Novartis, we're focused on transforming the business, making it an autonomous entity over the next 18 months that is able to compete as an independent unit within Novartis," Narasimhan said on a call with analysts on Wednesday.
Novartis's 2019 sales and profit growth guidance disappointed investors seeking more from Chief Executive Vas Narasimhan's efforts to focus the Swiss drugmaker on high-tech medicines while shedding non-core assets. The company sees net sales growing by a low- to mid-single-digit percentage, with core operating income up by a mid-single-digit rate, Novartis said on Wednesday. Shares in the world's biggest prescription drugmaker had slipped 1.1 percent by 1305 GMT, lagging a 0.2 percent decline in the Stoxx European Health Care Index.
The Basel, Switzerland-based company said it had net income of 51 cents per share. Earnings, adjusted for non-recurring costs, were $1.24 per share. The results missed Wall Street expectations. The average ...
Swiss drugmaker Novartis reported slightly weaker-than-expected quarterly earnings on Wednesday, prompting shares to fall more than 2 percent shortly after the opening bell.
Amgen's biggest moneymaker could face biosimilar competition this year, an analyst said Monday as he downgraded Amgen stock. Novartis is nearing a court decision on its Enbrel biosimilar.
The Swiss company, one of the world's biggest drugmakers, said the risk of Britain leaving the European Union, its biggest trading partner, without a deal had risen after Prime Minister Theresa May failed to get her deal through parliament last week. "Given the complex nature of the supply chain, government needs to implement a comprehensive continuity plan rapidly," Novartis said in a statement. Novartis's fastest-growing medicine is Cosentyx, the blockbuster medicine for psoriasis and other auto-immune disorders including ankylosing spondylitis.